Published • loading... • Updated
Thyroid Medication Recalled because It Could Be 'Superpotent'
Testing confirmed the lot could be stronger than labeled, and the company said 1,955 units were sold before the voluntary recall.
- In a notice posted to the Food and Drug Administration website on Monday, Auburn, Alabama-based Vitruvias Therapeutics Inc. issued a nationwide recall of 30-milligram thyroid tablets after testing confirmed the product is potentially "superpotent."
- Vitruvias Therapeutics distributed Lot 504950 nationwide from Jan. 31, 2025, to Sept. 30, 2025, with 1,955 of the 3,600 units released sold to direct accounts.
- Consuming "superpotent" tablets can cause hyperthyroidism, leading to rapid heart rate, weight loss, and hypertension; older adults, pregnant women, and infants face the highest risk of adverse effects.
- Patients currently taking the medication should not discontinue use without consulting their healthcare provider, as Vitruvias Therapeutics has not received any reports of adverse events tied to the recall.
- Vitruvias Therapeutics is notifying wholesalers to discontinue distribution and arrange for product destruction, while consumers with questions can contact the company regarding the medication, which expires Sept. 30, 2026.
Insights by Ground AI
29 Articles
29 Articles
Superpotent Thyroid Tablets Recalled in US
A drug manufacturer is recalling a single lot of thyroid tablets following tests confirming the potential for the medication to be too strong. The recall is applicable to 3,655 units of Thyroid Tablets, USP 30 mg, lot number 504950, distributed between Jan. 31, 2025, and Sept. 30, 2025, with an expiry date of Sept. 30, 2026, the company said in an announcement published by the Food and Drug Administration on Aug. 24. The items were distributed a…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources29
Leaning Left0Leaning Right1Center28Last UpdatedBias Distribution97% Center
Bias Distribution
- 97% of the sources are Center
97% Center
C 97%
Factuality
To view factuality data please Upgrade to Premium
